Although senior leadership has been re-organized, the actual consistency and interactivity of the team remains stable. In fact, Dr. DiPaola was appointed as Director of CINJ following multiple appointments at CINJ including Co-Leader of the Prostate Program, Chief of Medical Oncology and Associate Director for Clinical Science. Dr. Edmund Lattime, a prior Associate Director, was appointed to the position of Deputy Director in 2008 by Dr. DiPaola. Dr. Joseph R. Bertino remains as Chief Scientific Officer. Dr. Michael Reiss continues as Associate Director for Translational Science and has appropriately assumed oversight of all basic science and translational shared resources. Dr. Eileen White, a Program Leader since 2004, was appointed Associate Director for Basic Science and, following a move of her laboratories to the main CINJ building in New Brunswick, increased basic science mentorship at CINJ. Dr. Joseph Aisner is Associate Director for Clinical Science as in the 2004 review, and Dr. Susan Goodin has been appointed Assistant Director for Clinical Science and Director ofthe Office of Human Research Services. Stability in administration also remains, as Ms. Linda Barker continues as Associate Director for Administration and Planning. As a new leader. Dr. Helmut Zarbl was appointed Associate Director for Public Health Science, overseeing CINJ's efforts in prevention, control, and population science. Salary support for these individuals is requested only for the effort attributable to research-related activities.
The senior leadership supports the mission ofthe Cancer Institute of New Jersey (CINJ) as a National Cancer institute (NCI)-designated comprehensive cancer center to increase scientific depth and breadth in basic, clinical and public health sciences.
|Park, Kihan; Chen, Wenjin; Chekmareva, Marina A et al. (2018) Electromechanical Coupling Factor of Breast Tissue as a Biomarker for Breast Cancer. IEEE Trans Biomed Eng 65:96-103|
|Jang, Thomas L; Patel, Neal; Faiena, Izak et al. (2018) Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer. Cancer 124:4010-4022|
|Gupta, Apar; Ohri, Nisha; Haffty, Bruce G (2018) Hypofractionated radiation treatment in the management of breast cancer. Expert Rev Anticancer Ther 18:793-803|
|Patrizii, Michele; Bartucci, Monica; Pine, Sharon R et al. (2018) Utility of Glioblastoma Patient-Derived Orthotopic Xenografts in Drug Discovery and Personalized Therapy. Front Oncol 8:23|
|Herman, Joseph M; Jabbour, Salma K; Lin, Steven H et al. (2018) Smad4 Loss Correlates With Higher Rates of Local and Distant Failure in Pancreatic Adenocarcinoma Patients Receiving Adjuvant Chemoradiation. Pancreas 47:208-212|
|Celià-Terrassa, Toni; Bastian, Caleb; Liu, Daniel et al. (2018) Hysteresis control of epithelial-mesenchymal transition dynamics conveys a distinct program with enhanced metastatic ability. Nat Commun 9:5005|
|Zloza, Andrew (2018) Viruses, bacteria, and parasites - oh my! a resurgence of interest in microbial-based therapy for cancer. J Immunother Cancer 6:3|
|Paratala, Bhavna S; Chung, Jon H; Williams, Casey B et al. (2018) RET rearrangements are actionable alterations in breast cancer. Nat Commun 9:4821|
|George, Blessy; Joy, Melanie S; Aleksunes, Lauren M (2018) Urinary protein biomarkers of kidney injury in patients receiving cisplatin chemotherapy. Exp Biol Med (Maywood) 243:272-282|
|Moloughney, Joseph G; Vega-Cotto, Nicole M; Liu, Sharon et al. (2018) mTORC2 modulates the amplitude and duration of GFAT1 Ser-243 phosphorylation to maintain flux through the hexosamine pathway during starvation. J Biol Chem 293:16464-16478|
Showing the most recent 10 out of 775 publications